This topic contains a solution. Click here to go to the answer

Author Question: Internal sources of bureaucratic power include a. clientele groups. b. information and ... (Read 91 times)

sjones

  • Hero Member
  • *****
  • Posts: 520
Internal sources of bureaucratic power include
 
  a. clientele groups.
  b. information and expertise.
  c. vague legislative enactments.
  d. power-hungry administrators.

Question 2

An important source of bureaucratic power in the national government
 
  a. has its roots in administrators' thirst for power.
  b. is not in the phenomenon of clientele groups.
  c. is found in Article III of the Constitution.
  d. lies in the discretionary power of administrators.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

babybsemail

  • Sr. Member
  • ****
  • Posts: 304
Answer to Question 1

b

Answer to Question 2

d




sjones

  • Member
  • Posts: 520
Reply 2 on: Jul 13, 2018
Thanks for the timely response, appreciate it


mcabuhat

  • Member
  • Posts: 344
Reply 3 on: Yesterday
Gracias!

 

Did you know?

Barbituric acid, the base material of barbiturates, was first synthesized in 1863 by Adolph von Bayer. His company later went on to synthesize aspirin for the first time, and Bayer aspirin is still a popular brand today.

Did you know?

Less than one of every three adults with high LDL cholesterol has the condition under control. Only 48.1% with the condition are being treated for it.

Did you know?

In the ancient and medieval periods, dysentery killed about ? of all babies before they reach 12 months of age. The disease was transferred through contaminated drinking water, because there was no way to adequately dispose of sewage, which contaminated the water.

Did you know?

Russia has the highest death rate from cardiovascular disease followed by the Ukraine, Romania, Hungary, and Poland.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library